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Abstract: 
Alzheimer's disease (AD), the most common cause of dementia, has few clinical similarities to HIV-1-associated dementia (HAD). However, 
genes were identified related among these dementias. Discovering correlations between gene function, expression, and structure in the human 
genome continues to aid in understanding the similarities between pathogenesis of these two dementing disorders. The current work attempts to 
identify relationships between these dementias in spite of their clinical differences, based on genomic structure, function, and expression. In this 
comparative study, the NCBI Entrez Genome Database is used to detect these relationships. This approach serves as a model for future diagnosis 
and treatment in the clinical arena as well as suggesting parallel pathways of disease mechanisms. Identifying a correlation among expression, 
structure, and function of genes involved in pathogenesis of these dementing disorders, may assist to understand better their interaction with each 
other and the human genome. 
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Background: 
It is well known that clinically, Alzheimer's disease (AD) and HIV-1-
associated dementia (HAD) are distinct incurable dementing 
disorders [1].For the present study we hypothesized that there is a 
correlation between expression and structure/function of some genes 
for AD with HAD.  
 
AD is the most common form of dementia in the elderly population. 
The Alzheimer's association defines its warning signs as follows: 
memory loss, disorientation to time and place, poor or decreased 
judgment, misplacing objects, difficulty with performing familiar 
tasks as well as language and abstract thinking, and changes in mood, 
behavior, and personality, as well as loss of initiative [2].
 
 
Genetic factors have been implicated in the pathogenesis of AD. 
Khachaturian and Radebaugh [3] summarized that amyloid precursor 
protein (APP), presenilin I (PSEN1), presenilin II (PSEN2) and 
apolipoprotein-E (APOE) alleles are directly related to AD (Table 1 
in supplementary material) and characterized them according to the 
different types of AD. APP, PSEN1 and PSEN2 are associated with 
patients of early-onset AD, while apolipoprotein-E with those 
patients of late-onset AD (Table 1 in supplementary material). 
Familial or early onset AD develops from the age of 40 up to 60 or 
65 years and less than 10% of AD cases are of this type [4]. The other 
form of AD, sporadic or late-onset, is characterized by its abrupt 
development after the age of 60 to 65 and it is most frequently found 
in AD patients [4].   
 
Unlike neurological diseases such as muscular dystrophy and 
Huntington's disease, AD is not caused by mutations in a single 
gene, but rather the mutations of genes found on multiple 
chromosomes, when familial. Most cases of AD are sporadic and 
genetic cause has not been established. However, mechanisms 
appear to operate that associate the actions of genes involved in 
familial disease [1]. Possibly what is termed Alzheimer's disease 
may actually compose sub-components with different 
pathogenesis, sharing similar clinical features. Those clinical 
features involve insidious and progressive impairment in forming 
new memories, accompanied by varying degrees of deficit in 
visuospatial functioning, confrontation naming, problems solving 
and other cognitive areas that are accompanied by a gradual loss 
of independent functioning [5].  
 
Selkoe developed mechanisms for AD [6]. Pathogenesis of AD 
involves protein aggregation, termed neuritic plaques that mainly 
consist of the Aβ peptide. Aβ is a neurotoxic peptide that is coupled 
with plaque and tangle formation, eventually leading to neuron death 
(Figure 1a) [6]. Aβ is derived from proteolytic processed amyloid 
precursor protein gene (APP) [7]. The APP gene is located on 
chromosome 21 and mutations in this gene have been associated with 
AD  [6]. The amyloid cascade hypothesis states that altered APP 
metabolism involving a reduction in sAPPα and increased levels of 
Aβ (processed into several related oligopeptides), is a common 
feature of AD [6].   
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Verdile and colleagues [8] found a relationship between presenilins 
(PSEN) and their role in generation of Aβ. Mutations in PSEN1 and 
PSEN2 account for most autosomal dominant early-onset familial 
forms of AD. Verdile and colleagues stressed presenilin's vital role in 
the production of the Aβ protein that is found to accumulate in the 
brain of AD patients. It was previously shown by Khachaturian and 
Radebaugh [3] that intramembranous presenilin enzymes cleave the 
C-terminal fragment of APP resulting in Aβ release [8]. 
Consequently, it has been speculated by Popescu and colleagues [9] 
that PSEN1 and PSEN2 have a regulatory role in apoptosis of cells 
from patients with AD. Another protein, apolipoprotein-E, is 
associated with late-onset AD [10]. With three isoforms of the Apo-E 
gene,
 Apo-E2, -E3, and -E4, [11] Apo-E is found to be associated 
with AD. However, even with the discovery of these three AD-
associated genes, recent studies suggest that they constitute less than 
30% of the genetic variance (or the phenotypic variance found in a 
population of various genotypes) for AD and that, additional genetic 
factors remain to be identified [12]. 
 
Human immunodeficiency virus type 1 (HIV-1) enters the CNS 
during the early stages of HIV infection. HIV-associated dementia 
(HAD) consists of a progressive encephalopathy that results from 
impairment of normal CNS function by HIV-1 related injury. The 
symptoms that characterize HAD are broadly separated in categories 
that are termed: cognitive, motor, and behavioral as previously 
reviewed  [13]. The cognitive related category of symptoms 
traditionally resembled subcortical dementias, and included 
difficulties with concentrating, memory retrieval eventual 
degradation of all mental functions as the dementia progressed. 
However, evidence indicates that in the post-HAART era, cognitive 
deficits are now including deficits in learning and complex attention 
[14]. The motor associated symptoms include poor coordination, 
weakness in legs, inability to maintain balance, lack of grip in hands, 
decline in clarity of handwriting, loss of bladder or bowel control. 
The behavioral related symptoms include changes in personality such 
as increased irritability, apathy, loss of initiative and withdrawal from 
social contact. Other behavioral symptoms include depression, 
excitability, emotional outbursts, impaired judgment, and, on 
occasion, symptoms of psychosis (hallucinations, paranoia, 
disorientation, sudden rages) [13]. However, a syndrome 
characterized by lesser degrees of cognitive and motor deficit and 
less impairment in day-to-day functioning is termed HIV-associated 
minor cognitive motor disorder (MCMD).   
 
Neuropathogenesis of HAD involves infection of 
macrophage/microglia and astrocytes. Neurons are rarely infected 
directly by HIV-1 [13]. These cells produce toxins that initiate a 
series of biochemical reactions and signaling pathways that instruct 
neurons to commence apoptosis, leading to HAD. [15]. The 
macrophages and microglia also produce chemokines and cytokines 
that, in turn, affect neurons and other brain cells (e.g., astrocytes) 
[16]. The affected astrocytes that normally nurture and protect 
neurons, participate in the destruction of the healthy neurons [15]. 
 
Oxidative stress is another component of neuropathogenesis in 
neuropsychiatric disease [16]. One of many studies demonstrated that 
infected astrocytes produce highly toxic peroxynitrite from 
superoxide and nitric oxide radicals. Smith and colleagues [17] 
examined whether peroxynitrite is involved in Alzheimer's disease, 
and found the oxidative factor to result in carbonyl formation of 
macromolecules that, in turn, indicated peroxynitrite involvement. 
Smith's findings provide strong evidence that peroxynitrite is 
involved in the oxidative damage of Alzheimer's disease that is also 
found in HAD, in spite of its clinical differences. In addition, it is to 
be noted that Kuljis and colleagues [18] demonstrated that there was 
up to a 40-fold increase in the expression of the neuronal nitric oxide 
synthase in neurons associated with drug abuse and HIV infection.  
 
The expression of several dementia-related genes may be similar in 
both AD and HAD despite the clinical differences of these two 
diseases as well as their non-viral and viral causes, respectively. It is 
thus a counter-intuitive hypothesis to implicate possible relationships 
between gene interactions on the same chromosomes. Moreover, 
along this reasoning, human genes related to HIV genes, 
interactively, may regulate the dementias. The HIV-1 Rev protein 
[19] is one of the HIV's regulator genes that stimulates the production 
of HIV proteins, but suppresses the expression of HIV's regulatory 
genes (Table 6 under supplementary material) [19, 20]. This gene is 
involved in the transport of precursor mRNA from the nucleus into 
the cytoplasm. A similar sequence related to this protein was found in 
the human genome. Cullen [19] demonstrated an ancient family of 
viruses, known as HERV-K (human endogenous retrovirus K), 
derived from old world monkeys, and is hypothesized to have later 
evolved in Homo sapiens. According to Cullen, 30-50 copies of 
HERV-K exist in the human genome, and some of the copies appear 
to be transcriptionally active at low levels in normal testicular and 
placental tissue. Most importantly, Cullen and colleagues determined 
that the HERV-K viral protein, K-Rev, functions in a manner similar 
to the HIV Rev protein [19] in its ability to transport precursor 
mRNA to the cytoplasm of the host cell. The study provides evidence 
for the appearance of HIV-1-like interacting genes in the human 
genome. 
 
Methodology: 
Using the National Center for Biotechnology Information (NCBI) 
website, data was obtained and organized to examine the genetic 
comparison between AD and NeuroAIDS (Table 2 see supplementary 
material). This tool was the main “instrument” used in the 
preparation of this comparative study. Additional databases were also 
used. The databases found in Entrez Genome, and on the NCBI 
websites were utilized and the following human genes located: 
amyloid β, presenilin, Apolipoprotein, and HIV-1 associated genes. 
After conducting the individual searches, a comparison of similar 
chromosomal locales was made and presented in a Venn diagram 
(Figure 1b). The same chromosomal comparison was conducted for 
AD related genes and presented in another Venn diagram (Figure 1a). 
In addition to location comparison, the genes' functions associated 
with AD were compared to those associated with HIV-1-interacting 
proteins. Using the Online Mendelian Inheritance in Man (OMIM) 
link (Table 2 under supplementary material) the functions of the 
available genes were obtained, and compared to those found in the 
same chromosomes associated with both dementias as well as those 
found in different locales. 
 
Hypothesis  
This study targets three areas (gene structure, function, and 
expression) and explores genetic relationship between the AD and 
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hypothesize that in spite of the differences between the clinical 
presentations of AD and HAD, there may be similarities in the 
dementia-associated gene structure, function, and expression and 
HIV-1-related genes. As a corollary hypothesis, we further postulate 
that there are functionally related groups of genes involved in each 
dementia. The dementia-associated genes previously mentioned for 
AD and HIV-1 have a series of functions that are not restricted to 
these specific dementias [16, 21]. In addition, the association found 
between HIV-1-disease and AD, based on the peroxynitrite and the 
Rev-like sequence found in the human genome are both examples 
that support this hypothesis. Moreover, a further corollary to these 
hypotheses is that dementia-associated genes are in located in 
propinquity with one another on the chromosomes in the human 
genome. This may relate to chromatin structural changes and 
modifications that may occur when these genes undergo changes in 
genes expression [22].  
 
Results: 
The NCBI's database (including GeneBank and OMIM) provided 
information regarding the position of those genes linked with the 
dementias in order to determine whether they have similar 
chromosomal positions. Some genes have similar positions. The first 
comparison examined the AD related genes only, and found that 
these were mostly different from one another in location. For 
example, the Amyloid β associated genes were on chromosomes 
different from those of Apolipoprotein and presenilin (Figure 1a). 
These Aβ and Aβ-related genes were found on chromosomes 4, 5, 9, 
10, 11, 15, 16, 17, 20 and 21 (Figure 1a). The greatest association 
was discovered between the following genes: APBA3 (related to Aβ), 
APOE (related to Apolipoprotein), and PEN2 (related to presenilin). 
These genes were all located in chromosome 19 and in propinquity, 
as shown in Table 3 in supplementary material.  
 
The second comparison conducted for each AD gene compared them 
with those found related to HIV-1-associated genes. Amyloid β had 
genes related to HIV-1-associated genes on more than one 
chromosomal location. These locations were found on chromosomes 
4, 5, 11 and 17 (Table 4 in supplementary material). Presenilin genes 
also shared chromosomal locations with HIV-1-related genes on 
chromosomes 1, 2, 3, and 14 (Table 5, see supplementary material).  
 
However, it is important to note that there was a disparity discovered 
with Apolipoprotein E, as it was on chromosome 19, and had no loci 
relationships with the genes found linked with HIV-1-related genes. 
In addition, other genes found on chromosomes 6, 7, 8, 12, and 22, 
the X chromosome are HIV-1-interacting but had no shared 
chromosomal loci with AD-related genes (Table 6 in supplementary 
material). It is important to note also that there was no HIV-1 related 
gene found on the 23
rd or Y chromosome. A possible target of 
research is to explore further the hereditary capabilities and 
molecular biology of these genes.  
 
 
Figure 1: (a) Venn diagram that demonstrates the chromosomal relationship found with the human genes associated with all the AD related genes 
found. The Aβ related genes found on the chromosomes represented in diagram, as well as those of presenilin, and Apolipoprotein-E. (b) Venn 
diagram that demonstrates the chromosomal relationship found with the human genes associated with the AD related genes and those of HIV-1-
associated genes. The Aβ related genes were on the chromosomes represented in diagram, as well as those of presenilin, ApoE, and HIV-1 
associated genes. 
 
Discussion: 
This study describes and compares similar genes found related to AD 
vs. those related to HIV-1-associated disease at the level of structure, 
expression, and function. Specifically, genes linked with amyloid-β, 
presenilin and Apolipoprotein-E were compared to those found with 
HIV-1-related genes. Our study resulted in 19 genes related to each 
dementia as shown in Table 4 and Table 5 (tables in supplementary 
material). The amyloid precursor protein (APP) is closely linked to 
AD and previously reported, by Khachaturian and Radebaugh [3] 
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amyloid protein that forms the plaque core in Alzheimer's disease 
[23]. Although the chromosomal location of APP is not shared with 
any other gene associated to HIV-1, binding proteins that interact 
with APP are found to share this chromosome location with some of 
HIV-1 related genes (Table 3, see supplementary material). The 
cytoplasmic domain of APP binds to four human phosphotyrosine-
binding (PTB) proteins. With use of the yeast 2-hybrid screening 
applied to human brain, McLoughlin and Miller [24] discovered three 
of the four PTB to be amyloid beta precursor protein-binding, family 
B1 (APBB1), amyloid beta precursor protein-binding, family B2 
(APBB2), and amyloid-beta precursor protein (cytoplasmic tail) 
binding protein 2 (APBA2) located on chromosomes 11, 4, and 15 
respectably [24]. 
 
The HIV-1 interacting gene, HIV-1 induced protein HIN-1 
(HSHIN1), was found in position 4q31.21 with close chromosomal 
location to the PTB, APBB2 (Table 2 under supplementary material). 
Although its function has not been discovered, HSIN1 is a binding 
protein and some studies indicate that two alternatively spliced 
transcript variants encoding distinct isoforms have been found only in 
HIV-1 infected cells [19]. Its chromosome partner, APBB2 is a Fe65-
like protein, and is interrelated with a region of another amyloid 
precursor protein, amyloid beta (A4) precursor-like protein 2 
(APLP2) found in chromosome 11 (Table 4 see supplementary 
material) with a shared chromosome location of another gene linked 
to HIV-1 [25]. 
 
The deduced polypeptide of APLP2 contains a segment with high 
homology to the transmembrane-cytoplasmic domains of the A4 
amyloid protein found in brain plaques of Alzheimer disease patients 
[26, 27]. The other PTB found in chromosome 11, is APBB1 with an 
alternative name of Fe65 [28]. It contains 14 exons ranging in size 
from 6 to 735 bp [28]. Human Fe65 was discovered by Cao and 
Sudhof to be linked to the cytoplasmic tail of APP, and was found to 
form a multimeric complex with Fe65 as a nuclear adaptor protein 
[29]. A Fe65 like protein, APBB3 (Fe65-Like2) found in 
chromosome 5 showed binding capabilities to the intracellular 
domain of the Alzheimer disease amyloid precursor protein, both in 
vitro and in vivo [7]. The gene structure was determined by 
Tanahashi and Tabira [30] and this gene contained 13 exons, 
distributed over 6 kilodaltons (kD).  
 
The HIV-1 associated genes also located on chromosome 11 are 
HIV-1 Tat interactive protein (HTATIP) and HIV-1 Tat interactive 
protein 2 (HTATIP2) (Table 4, shown in supplementary material). 
With the use of affinity chromatography and the human 
immunodeficiency virus-1 (HIV-1) Tat protein, Xiao and colleagues 
[31] identified two Tat-interacting proteins, TIP30 (HTATIP2) and 
TIP56. Co-expression of TIP30 specifically enhanced transcription of 
Tat, the regulatory gene found related to the acceleration in the 
production of more HIV virus in transfected cells [20, 31, 32]. Their 
results not only identified TIP30 as one of the Tat-interacting 
proteins, but also as a specific coactivator that may enhance 
formation of a Tat-RNA polymerase II holoenzyme complex ex vivo 
and  in vitro  [32]. HTATIP that the authors called TIP60 (Tat-
interactive protein, 60-kD) is a gene with close relationship to APP. 
Cao and Sudhof [29] demonstrated that the cytoplasmic tail of APP 
forms a multimeric complex with the adaptor protein Fe65 (APBB2) 
and the histone acetyl-transferase Tip60 (HTATIP). This complex 
potently stimulates transcription, suggesting that release of the 
cytoplasmic tail of APP by gamma-cleavage may function in gene 
expression [29].
 
 
Zheng and colleagues [27] isolated a cDNA encoding amyloid beta 
precursor protein-binding protein-2 (APPBP2) that is also called 
PAT1 (protein interacting with APP tail-1) and mapped it to 
chromosome 17 [33]. APPBP2 is a deduced 585-amino acid 
hydrophilic protein, identical to the uncharacterized KIAA0228 
protein identified by Nagase and colleagues [33].It also lacks signal 
or transmembrane sequences, but contains N- and C-terminal, a 
coiled domain, several protein kinase C phosphorylation sites, and 4 
imperfect C-terminal tandem repeats.
  Several binding analysis 
determined that APPBP2 binds specifically to the tyrosine-containing 
APP-BaSS, and if a mutation of the tyrosine occurs, it will result in 
nonpolarized transport of APP. The same study also indicated that 
APPBP2 does not bind to the mutant APP-BaSS. 
Immunofluorescence microscopy demonstrated APPBP2 present in 
the Golgi region and overlaps the distribution of APP [26]. Along 
with its other functions, SDS-PAGE and immunoblotting showed that 
APPBP2 interacts with microtubules and is functionally associated 
with APP transport and processing [33]. On the same chromosome 
17, the HIV-1 associated gene CCL5 is found [34]. CCL5 that was 
designated as Regulated upon Activation, Normally T-Expressed, and 
presumably Secreted (RANTES), encodes a T cell-specific molecule 
[35]. By analysis of somatic cell hybrids and by in situ hybridization, 
using the cDNA probe, Donlon and colleagues [36] assigned the 
RANTES locus to 17q11.2-q12, with a secondary hybridization peak 
noted in the region 5q31-q34, which may represent the location of 
other members of the gene family With close proximity to APBB3, 
(Table 4 given under supplementary material) this second possible 
RANTES representative may have a genetic correlation with APBB3, 
whose function and structure was previously mentioned. Cocchi and 
colleagues  [37] who demonstrated that the chemokines RANTES, 
MIP-1-alpha, and MIP-1-beta are the major HIV-suppressive factors 
produced by CD8+ T cells that are involved in the control of HIV 
infection  in vivo. Arenzana-Seisdedos and colleagues
  [38] 
investigated a possible therapeutic agent for inhibition of HIV 
infection as a derivative of RANTES. The derivative, called 
RANTES (9-68), lacks the first 8 N-terminal amino acids, and has no 
chemotactic properties for leukocyte activation. This study found that 
the anti-HIV activity of RANTES and RANTES (9-68) showed some 
variability depending on the donor cells. The authors concluded that 
structurally modified chemokines can retain receptor affinity, inhibit 
HIV infection, though lack activation functions [38]. 
 
Bakhiet and colleagues [39] showed that, unlike other chemokines, 
expression of RANTES mRNA and protein, increases with age, thus 
producing possible dealings of AD and its pathogenesis. The effects 
produced by their study were then suppressed by anti-RANTES or 
anti-RANTES receptor antibodies and were enhanced by 
recombinant RANTES. Interferon-gamma (IFN-γ) is induced by 
RANTES and is required for RANTES' effects and only 10-week-old 
astrocytes expressed the IFN-γ receptor. Blocking IFN-γ with 
antibody, reversed the effects of RANTES, indicating that 
cytokine/chemokine networks are critically involved in brain 
development, thus, creating another possible interaction of AD 
related genes [39]. Yet another gene relationship was found, with the 
diminished transcription of RANTES, afforded by a regulatory allele Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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In1.1C, which is consistent with increased HIV-1 spread in vivo. It is 
this spread of viral infection that leads to the accelerated progression 
of Acquired Immunodeficiency Syndrome (AIDS) [40]. An, and 
colleagues  [40] observed the influence of four RANTES single 
nucleotide polymorphisms (SNPs) and their haplotypes on HIV-1 
infection and AIDS progression. Three of the four (403A in the 
promoter, In1.1C in the first intron, and 3-prime 222C in the 3-prime 
UTR) on chromosome 17, were related with increased frequency of 
HIV-1 infection. This study demonstrated In1.1C-bearing genotypes 
to account for 37% of the risk for rapid progression among African 
Americans, thus, a possibly important control of AIDS progression as 
well, in Africa. 
 
In addition to the Amyloid-β related genes, presenilin was another 
protein found to share chromosome locations with HIV-1-related 
genes (Table 5 in supplementary material). The mutations in PSEN1 
and PSEN2, account for most of all autosomal dominant early-onset 
familial AD [8]. These genes have been previously found in 
chromosomes 14 and 1 respectively [41, 42]. By linkage mapping, 
Sherrington and colleagues [42] defined a region containing the gene 
for early-onset Alzheimer disease type 3, which had been linked to 
chromosome 14 and encoded by 10 exons with at least 23 kD [43]. 
The structural analysis predicted an integral membrane protein with 
at least 7 transmembrane helical domains that was identified as 
presenilin 1 (PSEN1) [42]. Presenilins regulate APP processing 
through their effects on gamma-secretase, an enzyme that cleaves 
APP [44]. It is this cleavage that, according Scheuner and colleagues 
[45], that leads to the amyloid plaque formation caused by the 
mutations in PSEN1. Another role played by PSEN1 is its interaction 
with Cadherin proteins that Zhang and colleagues [27] showed in 
their study. They demonstrated that PSEN1 forms a complex with 
beta-catenin  in vivo that increases beta-catenin stability. These 
PSEN1 mutations reduce its ability to stabilize beta-catenin leading 
to the increased degradation of beta-catenin in the brains of 
transgenic mice.
 The beta-catenin levels are reduced in the brains of 
Alzheimer disease patients with these mutations. If beta-catenin 
signaling decreases or is lost, it will increase neuronal vulnerability to 
apoptosis induced by APP.
 Thus, mutations in the PSEN1 gene may 
increase neuronal apoptosis by varying beta-catenin stability, 
predisposing individuals to early-onset Alzheimer disease [27]. 
Along with PSEN1, the HIV-1 associated gene, LOC145414, was 
found with very limited information regarding its structure and 
function. It is similar to ribosomal protein L3 and HIV TAR binding 
protein, one that has 403 amino acids. Adams and colleagues
 [46] 
isolated the 3-prime region of an L3 cDNA as a human brain EST, 
and by somatic cell hybrid and radiation hybrid mapping analyses, 
Kenmochi and colleagues [46] mapped the human L3 gene to 
chromosome 22.
  This same similarity was found in other genes 
located on chromosomes 12 and X (Table 6 in supplementary 
material).   
 
The PSEN2 gene is located in chromosome 1, and Kovacs and 
colleagues  [48] demonstrated its expression patterns to be very 
similar to those of PSEN1 in the brain. PSEN2 has been identified to 
contain 12 exons, with ten coding and two derived from the 5-prime 
untranslated region [49]. It is also marked as a critical component of 
PSEN1 and gamma-secretase complexes, and its formation of 
Amyloid-β. Li and colleagues [50] suggested that PSEN2 and PSEN1 
play a role in chromosome organization and segregation. They 
discussed a pathogenic mechanism for familial AD, in which mutant 
presenilins cause chromosome mis-segregation during mitosis, 
resulting in apoptosis.
  An alternative hypothesis is that mutant 
presenilins that are not transported out of the endoplasmic reticulum 
appropriately may interfere with normal APP processing [50]. All 
possible interactions in the overall pathogenesis of AD can be 
observed with this interaction. The HIV-1 associated gene located on 
the same chromosome as PSEN2 is TAR (HIV) RNA binding protein 
1 (TARBP1) (Table 5 in supplementary material). This gene has been 
identified by Wu and colleagues [51] as a 185-kD protein that binds 
to the loop region of TAR RNA. This region (TAR RNA) is bound 
by the HIV Tat protein, a transcription-activating protein that 
activates the HIV-1 long terminal repeat (LTR). The HIV-1 LTR 
with the HIV genome is integrated into host DNA via the integrase 
protein and the LTR acts as a promoter-enhancer post-integration. 
Moreover, it influences the host cell's transcription machinery and 
alters the quantity of transcription.  
 
Gatignol and colleagues [52] discovered a second TAR binding gene 
(TARBP2) only difference is that this gene does not share 
chromosomal location with any of the AD genes found in this study 
(Table 6 shown in supplementary material). They purified a cDNA, 
TARBP2, and found that it encoded a 345-amino acid protein and 
Kozak and colleagues [53] mapped the TARBP2 gene on 
chromosome 12. with the same method, they also mapped the 
pseudogene (TARBP2P) on chromosome 8. TARBP2P was another 
HIV-1-related gene that did not share a chromosomal location with 
any of the AD associated genes. 
 
PSEN2 interacts with PSARL located on chromosome 3 (Table 2, see 
supplementary material) [8]. PSARL is a 379-amino acid protein with 
molecular mass of 42.2 kD. The HIV-1 related gene located on the 
same chromosome is CMKBR5 (also known as CCR5). Mummidi 
and colleagues [54] analyzed the structure of CMKBR5, and 
discovered that this gene contains four exons, and two introns. It was 
by radiation hybrid mapping that Liu and colleagues [55] localized it 
on chromosome 3p21. Dragic and colleagues [56] identified 
CMKBR5 as a co-receptor for the HIV-1. It was not only a co-
receptor but also a primary cofactor for the mediated entry of the 
HIV-1 envelope gp120. Later, Rottman and colleagues [57] showed 
CMKBR5 expression by bone marrow-derived cells that are targets 
for HIV-1 infection. Expression also included a subpopulation of 
lymphocytes and monocytes/macrophages, primary and secondary 
lymph organs and noninflamed tissues, neurons, astrocytes and 
microglia. CMKBR5 showed expression in other tissues like 
epithelium, endothelium, vascular smooth muscle, and fibroblasts. 
Rottman's results suggested that CCR5+ cells are engaged to 
inflammatory regions or sites resulting in the facilitated transmission 
of macrophage-tropic strains of HIV-1. 
 
Concurrently, the gene Interleukin-10 (IL10) was mapped on 
chromosome 1 by Kim and colleagues [44]. The study also showed 
the mouse IL10 to contain 5 exons at about 5.2 kilobase (kb). Shin 
and colleagues [58] identified associations for HIV-1 infection and 
progressions to AIDS with markers in the IL10 promoter region. 
Individuals who carried the 5′ promoter allele showed an increased 
risk in HIV-1 infection and progressed to AIDS. Protection or 
susceptibility was related to the CCR5 on chromosome 3 and 
previously mentioned [58]. T10 also showed to be closer to the AD Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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related gene PSEN2 in comparison to the other HIV-1 associated 
gene on chromosome 1 (Table 5 in supplementary material). Shin and 
colleagues [58] also noted studies by Rosenwasser and Borish who 
suggested that AIDS progression might be hindered by 
immunotherapeutic strategies similar to those of IL10.   
 
An additional gene found was Calsenilin (CSEN), a presenilin 
binding protein, identified as a neuronal protein found on 
chromosome 2, and binds to calcium [59] (Table 2, under 
supplementary material). Using the yeast 2-hybrid system with the 
last 103 amino acids of the presenilin-2 protein, Buxbaum and 
colleagues  [59] identified CSEN to interact with both presenilin-1 
and presenilin-2 in cultured cells and regulated the levels of a 
proteolytic product of presenilin-2. Their conclusions led to the 
understanding that calsenilin may mediate the effects of wild type 
and mutant presenilins on apoptosis and on Aβ formation. Later 
studies by Leissring and colleagues [60] suggested that calsenilin, or 
its downstream effectors, may represent feasible targets for 
therapeutic intervention in Alzheimer disease. The presenilin C-
terminus is the domain relevant for calcium signaling effects and 
offers a method for future clinical AD therapy.  
 
On the same chromosome, the HIV-1 associated gene is HIV-1 Rev-
binding protein (HRB) (Table 5 see supplementary material) [61]. 
Bogerd and colleagues [62] showed that HRB binds to the Rev 
activation domain in vitro and in vivo and to functionally equivalent 
domains in Rev proteins from diverse viruses. Another study, by 
Sanchez-velar and colleagues [63], concluded that HRB is a cellular 
Rev cofactor that is essential for the nuclear support of the viral 
RNAs, a crucial factor needed for the survival of its pathology. An 
additional Rev interacting protein is also found in chromosome 12, 
although with no AD associated genes located on this chromosome, it 
is still cited for its function. It has been assumed that its function and 
interaction with HIV-1 Rev is only a name analysis with no 
publications describing this interaction. An additional gene (HRBL) 
related to the Rev/Rex activating domain-binding protein on 
chromosome 7, with also no sharing of AD associated genes. 
 
Along with those genes found to share the same chromosome 
location, there were still several that did share the same chromosome 
locus with AD related genes and have indirect similarity with other 
genes found in this study. Those related to HIV-1 found on 
chromosome 6, 7, 8, 12, and 22 or X are LOC442267 and 
LOC401233 on 6; HRBL on 7; LOC442391 and TARBP2P on 8; 
HRB2, HIVE1 and TARBP2 on 12; and HTATSF1 on X (Table 2 
and Table 6 in supplementary material). The gene, LOC442267, 
found in chromosome 6 is an HIV-1 Nef interacting protein. The Nef 
protein in the HIV genome is one that interacts with the host cell 
signal transduction proteins to provide it with long-term survival of 
the infected T cells and to destroy non-infected T cells [10]. Baur and 
colleagues  [15] reported that Nef associates with two different 
kinases. This study concluded that deletion of a short α-helix in the 
N-terminus (composed of all Nef proteins) significantly reduces 
virion infectivity. In turn, this gene (LOC442267) interacts with this 
crucial protein found in the HIV-1 genome. The HIVE1 gene on 
chromosome 12 had no chromosomal partner with AD associated 
genes studied (Table 6 under supplementary material). Findings by 
Hart and colleagues [64] attempted to identify the human 
chromosomes that encode cellular factors that in the presence of tat, 
support enhanced HIV gene expression. Their study of hybrid cell 
clones from the fusion of human and Chinese hamster ovary cells 
showed that human chromosome 12 and the HIV tat gene are 
necessary for high levels of viral gene expression. Although, with 
similar findings reported by Newstein and colleagues [65], this 
mechanism is not likely to be true, because cell surface CD4, 
detected by immunostaining and flow cytometry, was present in only 
one of the four hybrid clones that produced a high level of the virus.
 
Probably this alone is capable of stimulating HIV gene expression 
and replication. Apolipoprotein-E the allele was correlated with late-
onset AD did not have an HIV-1 related gene in its same 
chromosome, a possible indication that late-onset AD has no genetic 
relationship to that of the genes found to interact with HIV-1 genes. 
Another HIV-1 related gene, HTATSF1, was located on the 22
nd 
chromosome, the X chromosome. HTATSF1 is a stimulatory factor 
of the tat gene, and the regulatory gene found related to acceleration 
in the production of more HIV virus in transfected cells
 previously 
mentioned  [19]
  (Table 2 see supplementary material). This tat 
stimulator has shown, with the use of immunoblot analysis as a 140 
kD phosphoprotein. This study suggested, HTATSF1, to mediate a 
broadly active cellular process. Another analysis (binding) showed it 
to weakly associate with the tar RNA, another HIV regulatory gene.  
 
Conclusion: 
In spite of the differences between AD and HAD clinically, we 
hypothesize a relationship in gene location, function, and expression 
between AD and HIV-associated disease. AD and HIV-1-associated 
disease were reported to share series of genes that directly deal with 
their organization and pathology. The functionality of a related group 
of genes involved in each disease was shared between those in this 
comparison. The dementia related genes were closely located on the 
chromosomes with the HIV-1-associated genes.  
 
Those AD-associated genes are functionally related to one another as 
APP-related and binding proteins. Briefly, some of their functions 
were to link to the cytoplasmic tail of APP and to other amyloid-β 
precursor-like proteins (APLP2). This conclusion suggests further 
research in this particular area of AD pathology, by questioning the 
detailed function of these specific proteins and creating a possible 
alternative treatment. Along with this association, the connection 
between some of the Amyloid-β precursor protein and HIV-1 
interacting genes generated the following genes: HSHIN1, 
LOC391810, HTATIP2, HTATIP, and CCL5. Another possible 
relationship and a target of future research, is the possibility of 
having a RANTES (CCL5) representative in the same chromosomal 
region of an Amyloid-β related gene. With continued research in this 
region, the gene may be located and eventually lead to analyzing its 
structure, function, and expression, with a possible creation of a 
therapeutic agent for inhibition of HIV-1 infection and ascertaining 
its relationship with AD. 
 
The presenilins also are genes needing further investigation. PSEN1 
and PSEN2, have regulatory control of APP processing. The 
investigation of this issue provides a better understanding a possible 
treatment of AD. Briefly, they show a role in chromosome 
organization and segregation, two very important factors related to 
chromosomal disease as well as their effects on gamma-secretase and 
APP formation. Their binding protein, CSEN regulates the levels of a 
proteolytic product of presenilin-2. This finding may lead to the Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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understanding of calsenilin on its ability to mediate the effects of 
wild type and mutant presenilins on apoptosis and on beta-amyloid 
formation. CSEN could then be characterized as a critical gene in the 
pathogenesis of AD and possible target for therapeutic involvement 
in AD. This produces another aim of research to find how this 
capability might prevent APP regulation in AD patients.  
 
It can be concluded that those genes able to bind to the HIV-1 
regulatory genes (tat, rev, Nef, and env) were found to have specific 
function in pathogenesis within HIV-1-related disease. This 
possibility produces a further goal to examine how these regulatory 
genes can be altered by the interaction of their binding-related genes. 
With the speculation that there already exists Rev-like sequences in 
our genome, one can further study their interaction with their binding 
protein (HRB) to possibility control its ability to control HIV-1 
proteins in host cells. Another possible area of research is generated 
with the gene LOC442267, in which this gene is able to interact with 
nef. If its complete function and expression were known, this might 
be another key to fully understand the pathogenesis of HIV-1 and 
possibly produce treatments to aid in its suppression. Along with 
these HIV-1 associated genes, CCL5, has a possible relationship with 
an Aβ binding protein, APBB3. This gene has the ability to suppress 
the development of AIDS, block HIV infection, and diminish 
transcription. A possible result of this research may be to reverse 
transcription induction processes and, thus, decrease the chances of 
the development of AIDS. Future work will correlate possible 
statistical relationships as well as a detailed functional analysis. In 
addition, sequence similarities among the various gene groups will be 
analyzed. 
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Supplementary material 
 
Gene Chromosome  Early-onset  Late-onset 
Amyloid precursor protein  21  Ages 40-60  No 
Presenilin I  14  Ages 30-50  No 
Presenilin II  1  Ages 30-65  Rare 
Apolipoprotein-E 19  Rare  Ages  60-75 
Table 1: Genes Related to Alzheimer's disease [65].
 
 
S.no.  Protein name  Gen Id  Gene name 
1       Calsenilin   604662  CSEN 
2       HIV-1rev-bindingprotein  600862  HRB 
3       HIV-1tat stimulatory factor1  300346  HTATSF1 
4       HIV type1 expression1  143055  HIVE1 
5       presenilin-associated rhomboid-like protein  607858  PSARL 
6       ribosomal protein l3  604163  RPL3 
7       tar rna-binding protein 1  605052  TARBP1 
8       amyloid beta a4 precursor protein-binding, family b, member 2  602710  APBB2 
9       amyloid beta a4 precursor protein-binding, family b, member 1  602709  APBB1 
10   amyloid beta a4 precursor-like protein 2; aplp2”  104776  APLP2 
11   amyloid beta precursor protein-binding protein 2  605324  APPBP2 
12   chemokine, cc motif, ligand   187011  CCL5 
13   fe65-like 2  602711  APBB3 
14   HIV-1 tat-interacting protein 30-kd  605628  HTATIP2 
15   HIV-1tat-interacting protein   601409  HTATIP 
16   presenilin 1  104311  PSEN1 
17 presenilin  2  600759  PSEN2 
18  LOC442267, similar to T-complex protein 1, eta subunit (TCP-
1-eta) (CCT-eta) (HIV-1 Nef interacting protein)   
442267  LOC442267    
19  HIV-1 rev binding protein 2  11103  HRB2    Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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20  HIV-1 induced protein HIN-1,  KIAA1046  54726  HSHIN1    
21  LOC145414   similar to ribosomal protein L3; 60S ribosomal 
protein L3; HIV-1 TAR RNA-binding protein B 
30583118  LOC145414    
Table 2: Dementia associated genes in NCBI, OMIM.
 
 
Name Additional  description/function Chromosome  Location  Distance  (bp) 
APBA1  9q13-q21.1  amyloid beta (A4) precursor protein-binding, 
family A, member 1 (X11) 
9q13-q21.2  69.27M – 69.53M 
APPL1  amyloid beta (A4) precursor protein-like 1 
9 
9q31-qter   57.24M-57.28M 
APBB1IP  amyloid beta (A4) precursor protein-binding, family B, 
member 1 interacting protein 
10p12.1 26.76M-26.89M 
LOC387643    similar to amyloid beta (A4) precursor protein-binding, 
family B, member 1 interacting protein; proline-rich protein 
73; Rap1-interacting adaptor molecule 
10p12.1 26.91M-26.98M 
C10ORF51     similar  to  amyloid  beta (A4) precursor protein-binding, 
family B, member 1 interacting protein; proline-rich protein 
73; Rap1-interacting adaptor molecule 
10 
10q21.1  
APBA2  amyloid beta (A4) precursor protein-binding, family A, 
member 2 (X11-like) 
15q11-q12   27.00M-27.19M 
LOC390566   similar to amyloid beta A4 precursor protein-binding, family 
A, member 2; neuronal munc18-1-interacting protein 2; X11-
like protein; phosphotyrosine-binding/-interacting domain 
(PTB)-bearing protein; neuron-specific X11L protein; adapter 
protein X 
15q14 32.48M-32.49M 
LOC390569   similar to amyloid beta A4 precursor protein-binding, family 
A, member 2; neuronal munc18-1-interacting protein 2; X11-
like protein; phosphotyrosine-binding/-interacting domain 
(PTB)-bearing protein; neuron-specific X11L protein; adapter 
protein X 
15 
15q14 32.635M-32.636M 
APPBP1  amyloid beta precursor protein binding protein 1, 59kDa  16  16q22   65.39M-65.42M 
APBA3 19p13.3 amyloid beta (A4) precursor protein-binding, family 
A, member 3 (X11-like 2) 
19** 19p13.3  37.01M-37.126M 
APBA2BP  20q11.22    amyloid beta (A4) precursor protein-binding, 
family A, member 2 binding protein 
20 20.q11.22  31.7M-31.72M 
APP  21q21.3 amyloid beta (A4) precursor protein (protease nexin-
II, Alzheimer disease) 
21 21q21.3  26.17M-26.46M 
PEN2  19q13.13 presenilin enhancer 2  19**  19q13.13  40.928M-40,929M 
APOE   19q13.2 Apo-lipoprotein E (late onset AD)  19**  19q13.2  50.100M-50.1004M 
Table 3: Genes found in Alzheimer's disease and their particular location in the human genome excluding those that shared loci with HIV-1-
associated genes. Note that chromosome 19 has genes from Amyloid B, presenilin, and Apolipoprotein groups. *Data obtained from NCBI 
Entrez Genome [18, 41, 53]. Alzheimer's disease related genes with their corresponding proteins. ***blank = no information was obtained 
 
Amyloid β related genes  HIV-1 related genes 
Location/Description Symbol  Distance 
(bp) 
Chromo
some 
Distance (bp)  Symbol  Location/Description 
4p14  amyloid beta (A4) 
precursor protein-binding, 
family B, member 2 (Fe65-
like) 
APBB2 41.05M-
41.06 
4 14.645M-
14.641M 
HSHIN1  4q31.21 HIV-1 induced protein 
HIN-1 
5q31  amyloid beta (A4) 
precursor protein-binding, 
family B, member 3 
APBB3 13.991-
13.992M 
5 92.251M-
92.252M 
LOC39181
0 
  5q14.3 similar CCT7 
 11p15  amyloid beta (A4) 
precursor protein-binding, 
family B, member 1 (Fe65) 
APBB1 63.72M-
63.97M 
20.341M-
20.361M 
HTATIP2  11p15.1  HIV-1 Tat interactive 
protein 2, 30kDa 
11q24 amyloid beta (A4) 
precursor-like protein 2 
APLP2 129.4M-
129.5M 
11 
65.23M-65.24M HTATIP  11q13  HIV-1 Tat interactive 
protein, 60kDa Bioinformation by Biomedical Informatics Publishing Group                                             open access 
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17q21-q23 amyloid  beta 
precursor protein (cytoplasmic 
tail) binding protein 2 
APPBP2 55.87M-
55.95M 
17  31.22-31.23M  CCL5  17q11.2-q12 HIV-1 disease, 
delayed progression of; HIV-1 
disease, rapid progression of 
Table 4: Amyloid β and HIV-1 associated dementia related genes with their locations in the human genome. *Data gathered from NCBI Entrez 
Genome [49, 53, 60]. **Bold text highlights the proximity of these genes to one another on the chromosome   
 
Presenilin related genes  HIV-1 related genes 
Location/Description Symbol  Distance 
(bp) 
Chromo
some 
Distance (bp)  Symbol  Location/Description 
230.8M-230.9M TARBP1  1q42.3 TAR (HIV) RNA 
binding protein 1 
1q31-q42 presenilin  2 
(Alzheimer disease 4) 
PSEN2 22.336M-
22.339M 
1 
203.32M-
203.33M 
IL10  1q31-q32 HIV-1, susceptibility 
to; Graft-versus-host disease, 
protection against 
 2q21.1 calsenilin, 
presenilin binding protein, 
EF hand transcription factor 
CSEN 95.38M-
95.47M 
2 228.16M-
22824M 
HRB  2q36.3  HIV-1 Rev binding 
protein 
3q27.3 presenilin 
associated, rhomboid-like 
PSARL 185.02M-
185.08M 
3  46.38M-46.39M  CCR5  3p21 HIV infection, 
susceptibility/resistance to 
14q24.3 presenilin  1 
(Alzheimer disease 3) 
PSEN 1 †  72.67M-
72.75 
14 56.3M-56.5M  LOC14541
4 
14q22.3  similar to ribosomal 
protein L3; 60S ribosomal 
protein L3; HIV-1 TAR RNA-
binding protein B 
Table 5: Presenilin and HIV-1 associated dementia related genes with their locations in the human genome. *Data obtained from NCBI Entrez 
Genome [41, 49, 60]. **Bold text highlights the idea of these genes being close to one another on the chromosome. †Directly found to be 
associated with Alzheimer's disease. 
 
Chromosome Distance  (bp)  Symbol  Description 
150.293M-
150.294M 
LOC442267  similar to T-complex protein 1, eta subunit (TCP-1-eta) (CCT-eta) (HIV-1 Nef 
interacting protein) 
6 
2.966M-2.968M  LOC401233  similar to HIV TAT specific factor 1; cofactor required for Tat activation of HIV-
1 transcription 
7  99.78M-99.80  HRBL  7q22.1 HIV-1 Rev binding protein-like 
104.740M-
104.741M 
LOC442391  similar to ribosomal protein L3; 60S ribosomal protein L3; HIV-1 TAR RNA-
binding protein B 
8 
80.64M-80.65M  TARBP2P  8q22-q24  TAR (HIV) RNA binding protein 2 pseudogene 
74.1M-74.19M  HRB2  12q21.1 HIV-1 rev binding protein 2 
  HIVE1  12q11-q13.3 human immunodeficiency virus type 1 (HIV-1) expression 
(elevated) 1 
12 
52.180M-
52.186M 
TARBP2  12q12-q12 TAR (HIV) RNA binding protein 2 
X 135.30M-
135.32M 
HTATSF1  Xq26.1-q27.2 HIV TAT specific factor 1 
Table 6: HIV-1 associated dementia genes found in human genome not structurally related to genes found with Alzheimer's disease. *Data 
obtained from NCBI Entrez Genome [49, 60]. **blank = no information was found. 
 
 